Olfactory and neurological manifestations of acute and post-acute murine COVID-19
Project Number5R01AI129269-07
Former Number5R01AI129269-05
Contact PI/Project LeaderPERLMAN, STANLEY
Awardee OrganizationUNIVERSITY OF IOWA
Description
Abstract Text
Abstract
SARS-CoV-2, the cause of COVID-19, continues to cause widespread infection and morbidity, but death rates
have decreased as most of the world has either been infected or vaccinated or both. However, at the same time,
it has become clear that many patients have developed long term sequelae. These sequelae, called PASC (Post
Acute Sequelae of COVID-19), affect many organ systems even though virus is found at autopsy in nearly all
studies only in the respiratory and gastrointestinal tracts. One common symptom of acute COVID-19 is anosmia.
Recovery of olfactory function is often incomplete in patients. However, only supporting (sustentacular) cells and
not olfactory sensory neurons are infected in patients, raising the question of how infection of a supporting cell
could have such profound effects on olfaction. In addition, neurological disease is also present in many patients
with PASC. Many of these manifestations reflect ongoing inflammation (usually observed on autopsy), but the
basis of these inflammatory changes is unclear since virus cannot be detected. We have isolated a mouse-
adapted virus that causes severe acute respiratory disease in infected mice, as well as persistent signs of
disease is the lungs and brains months after the acute infection has resolved. Infected mice develop anosmia,
as well as long term behavioral abnormalities and defects in neurotransmitter expression, but virus is not present
in the brain. Our central hypothesis is that ongoing inflammation is a major contributory factor in the observed
dysfunction in the olfactory and neurological systems. This hypothesis will be addressed in the following specific
aims: Specific Aim 1: To understand the relationship between sustentacular cell infection and olfactory
dysfunction and to understand the basis of chronic changes in the brains of SARS-CoV-2-infected mice. Acute
and chronic changes in olfactory pathways will be probed using electrophysiological and olfactory
measurements. These changes will be related to sustentacular function and gene expression. Parts of the brain,
such as the substantia nigra, which are affected in neurodegenerative diseases such as Parkinson’s disease will
be studied. Our preliminary results show changes in neurotransmitter expression in the substantia nigra several
months after infection, supporting this hypothesis. Specific Aim 2: To examine the role of viral macromolecular
products and infiltrating inflammatory cells in the brains of mice infected with SARS-CoV-2 in the development
of PASC. Using molecular and immunological approaches, we will assess whether inflammation results from
extrapulmonary SARS-CoV-2 infection and rapid clearance within the first days of infection (‘hit and run’). Using
a mouse in which infiltrating myeloid cells can be readily identified, we will analyze localization, function and
gene expression of these infiltrating myeloid cells, as well as of T cells that infect the brain chronically. The
ultimate goal is to relate these changes in inflammation to the neurological/olfactory dysfunction that we
characterize in Aim 1.
Public Health Relevance Statement
Narrative
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) causes substantial morbidity and mortality in
humans. It has become apparent that, even as most people have developed an immune response to the virus
either from infection or vaccination, long term sequelae of the infection will be a burden on human health for
years to come. This project will examine long term effects of the infection in the olfactory system and brain, with
the ultimate goal of identifying novel therapeutic targets.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
062761671
UEI
Z1H9VJS8NG16
Project Start Date
23-September-2016
Project End Date
31-October-2028
Budget Start Date
01-November-2024
Budget End Date
31-October-2025
Project Funding Information for 2025
Total Funding
$636,357
Direct Costs
$409,233
Indirect Costs
$227,124
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$636,357
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI129269-07
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI129269-07
Patents
No Patents information available for 5R01AI129269-07
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI129269-07
Clinical Studies
No Clinical Studies information available for 5R01AI129269-07
News and More
Related News Releases
No news release information available for 5R01AI129269-07
History
No Historical information available for 5R01AI129269-07
Similar Projects
No Similar Projects information available for 5R01AI129269-07